Dr. Trikha is the President and CSO of Triphase Accelerator and Board member of Triphase Accelerator since 2014. He has 20 years of drug discovery and development experience, that has been instrumental in fund raising at Triphase, leading the filing of oncology INDs, and initiating multiple Phase 1/2 clinical trials in North America, Europe and Australia.
Since Triphase establishment, he was responsible for the non-clinical and clinical development of marizomib, a novel brain penetrant proteasome inhibitor, for glioma, CNS malignancies, myeloma, GLP toxicology, and developed an oral formulation. Celgene acquired marizomib in December 2016 and is advancing the drug to Phase 3 registration studies. His group is now leading a novel CD22 antibody drug conjugate (ADC) for lymphoma that site specifically delivers two cytotoxic payloads per antibody.
Prior to Triphase, he was Associate VP of translational medicine & clinical development at Ambit Biosciences, project leader for the AML drug, quizartinib (a FLT-3 kinase inhibitor), project leader for AC480, a brain penetrant pan-EGFR inhibitor, and was responsible for lung, breast & glioma IND/clinical studies.
Prior to Ambit, he was Director of BioOncology Early Development at Genentech and Assistant Director of oncology research at Centocor (Johnson and Johnson). At Genentech, Dr. Trikha had a joint appointment in Research and Development and managed the BioOncology Early Development portfolio of small molecules, mAbs and ADCs. He built a cross-functional group that advanced programs from candidate nomination through clinical proof of concept. Two of the projects are now approved: Kadcyla® (Herceptin-DM1) and Erivedge® (GDC 0449 Hedgehog inhibitor). He was a JSC member for the apoptosis/bcl-2 collaboration (ABT 263) with Abbott, Genentech and WEHI, worked closely on MetMab (anti-cMET one armed antibody), GDC 0941 (PI3 kinase inhibitor), CD79b ADC, and IAP antagonist GDC0152. At Centocor/JNJ, Trikha held various positions in clinical pharmacology and oncology drug discovery. His basic research focused on angiogenesis, inflammatory cytokines (TNF and IL6), targeted immunoliposomes, mAbs and ADCs. He is co-inventor of siltuximab (CNTO 328 an anti-IL6 mAb called Sylvant ®), CNTO 95 (an anti-integrin mAb), IMGN388 (an anti-angiogenic ADC), and EGFR targeting STEALTH® immunoliposomes. IMGN388 and CNTO 95 completed Phase I and Sylvant ® is approved for Castleman’s disease.
Dr. Trikha is interested in advancing first or best in class drugs, cell signaling, tumor immunology, apoptosis, protein homeostasis, and developing biomarkers for predicting response and toxicity. He has published 40 papers, filed multiple patents and presented at AACR, ASCO, ASH, and EHA. He received his BS from California State University, LA, PhD from University of Southern California, and was an Assistant Professor of Research at Wayne State University prior to joining industry.
Dr. Trikha is also a Board Member for EnCycle Therapeutics (a macrocycle company).
His hobbies are high altitude hiking and understanding the molecular biology of meditation. He has hiked up to Mt Everest Base Camp/Kalapathar (18,202 ft) and Mt Whitney (14,494 ft).
Grant Gibson is an experienced finance executive with over 20 years of progressive global experience focused on the biotech, pharma and life science industries. Grant has overall responsibility for all areas of finance and the day-to-day operations of Triphase, including strategic financial planning, audit & accounting, tax, and treasury as well as human resources.
Most recently, Grant was the CFO of Clearstone Central Laboratories – a private global central laboratory business spun-out from MDS Inc. Before joining Clearstone, Grant held senior finance positions with MDS Inc. – a large Canadian public CRO business, and Elan Pharmaceuticals – a global public pharmaceutical company focused on neurodegenerative and autoimmune diseases. Prior to entering industry, Grant was a valuation expert for Deloitte & Touche in San Francisco, providing valuation consulting services to many leading global pharma/biotech and technology companies. Grant began his career with Ernst & Young and held various positions of increasing responsibility in the firm’s Corporate Finance and Audit & Assurance practice areas in both Canada and the United States. Grant obtained his Honors Business Administration (HBA) degree from the Richard Ivey School of Business at the University of Western Ontario and is a Chartered Professional Accountant (CPA) and Chartered Business Valuator (CBV).